Participated · Equity · Jun 2018

Bainbridge Health developed a medication-management software platform that uses data from infusion pumps to help make medication applications error-proof. Founded in 2016 as a spinout from the Children’s Hospital of Philadelphia, the company initially focused on that pump-data platform. Under CEO Joseph Kaupp the firm is expanding the product into a broader suite of tools—Kaupp likens the shift from Microsoft Word to the full Microsoft Office suite. The expansion is intended to combat medical errors, described in the article as a leading cause of death in the country. Financially, Bainbridge recently received a $1.6M infusion and all told has raised a $3.5M seed round split across multiple tranches. Investors in the recent infusion include BioAdvance, CHOP, Chestnut Street Ventures and private investors. Bainbridge Health is a CHOP spinout that develops a software platform geared at managing infusion pumps. The company recently raised $1.3 million in a seed round to continue building out its platform. CEO Joseph Kaupp said the funding will be used to expand the scope and functionality of the technology, advance the company’s implementation pipeline, and increase sales efforts. The raise is documented in an SEC filing. The company has been identified as a realLIST honoree. Bainbridge Health builds a SaaS medication-management platform that ingests and cleans siloed clinical data to reduce medication safety errors. Its initial product optimizes the workflow and data integration for Smart Infusion Pumps, automating data-clerking tasks clinicians currently do manually. The startup was incubated at the Children’s Hospital of Philadelphia and spun out on July 7, with CHOP providing an undisclosed equity investment. BioAdvance also supplied a $54,000 note to get the company started. The three-person team is based in a Center City coworking space in Philadelphia and plans to have the system live in two hospitals in November. Leadership says the infusion-pump work is the beginning of a platform they will leverage to address other verticals in medicine.

Participated · Equity · Mar 2017

Velano Vascular develops vascular access technologies for hospital inpatients and is led by CEO Eric M. Stone. Its FDA-approved PIVO device expands the use of peripheral IV lines for frequent, high-quality blood draws. The device is positioned to deliver painless, compassionate care for patients, improve safety for caregivers, and offer a more financially responsible alternative for health systems. The company provides a family of products that enable blood draws from indwelling peripheral IV catheters. Velano intends to use newly raised funds to accelerate commercialization and to launch additional novel inpatient medical device solutions. As of the latest tranche, the company has raised more than $50 million in total funding. Velano Vascular develops human-centered vascular access technologies and is based in San Francisco. The company is advancing the PIVO™ needle-free, single-use disposable device that enables high-quality blood samples via indwelling peripheral IV lines. PIVO is intended to reduce hospitals' reliance on repeat needle sticks and central line access, improving the blood draw experience for patients and practitioners. Velano raised $17M in financing to scale and commercialize its family of vascular access technologies. Backers on the financing included a publicly traded healthcare company and a global supplier alongside existing investors. The company is led by CEO Eric M. Stone. Velano Vascular develops a single-use, disposable device intended to standardize blood draws through patients' existing peripheral IV (PIV) catheters, reducing reliance on repeat needle sticks and central line blood draws. The company aims to improve the care experience for hospitalized patients and their practitioners and is advancing its technology for both adult and pediatric populations. It is working to better understand and evaluate the technology in pediatric patients and will initiate pilot programs this year exploring the device in medical centers and departments that serve adult and pediatric patients. Velano raised an additional $3.5M to support development and commercialization of its inpatient blood-draw technology and had completed a $5M Series A in January 2015. Leadership includes co-founder and CEO Eric M. Stone and newly added VP of Manufacturing and Operations Quinton J. Farrar. The company is based in San Francisco and also maintains an office in Philadelphia. Velano Vascular develops patented medical technology intended to reduce needle sticks during the inpatient blood-draw procedure and to enhance safety for providers. The company’s core product is a vascular access device aimed at improving blood-draw safety and workflow in hospitals. Velano was founded in 2012 and is led by president Pitou Devgon, MD, and CEO Eric M. Stone. It is based in Philadelphia, PA and San Francisco, CA. The company plans to use recently raised capital to move into clinical evaluation and into early commercialization with select hospital partners. The articles do not report revenue or user metrics.

Participated · Series B · May 2014

Spark Therapeutics develops curative, one-time gene therapy products targeting rare, debilitating diseases. Its lead gene therapy candidate for RPE65-related blindness is in Phase 3 clinical trials and could be the first treatment for patients with inherited retinal dystrophies. The company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders. Spark also operates a proprietary manufacturing platform that has supported human gene therapy trials across diverse therapeutic areas and routes of administration. It plans to use recent financing to advance its pipeline, including the lead Phase 3 program for RPE65-related retinal dystrophies, and to support company growth over the next three years. Jeffrey D. Marrazzo is co-founder and CEO, and The Children’s Hospital of Philadelphia is a co-founder.